Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Alzheimer’s Divide: Wyeth Phase II Underscores Key Choice For Sponsors

Executive Summary

Wyeth/Elan's Phase II bapineuzumab trial for Alzheimer's disease did not impress investors, but the sponsors are convinced they made the right bet in how they designed the study

You may also be interested in...



Wyeth Alzheimer’s Drug Gets Extra Patent Life Under Court Ruling

Wyeth's Alzheimer's drug bapineuzumab won an additional eight months of patent coverage under a federal court ruling that found the U.S. Patent and Trademark Office had misinterpreted a law governing agency delays in processing patent applications

Wyeth Alzheimer’s Drug Gets Extra Patent Life Under Court Ruling

Wyeth's Alzheimer's drug bapineuzumab won an additional eight months of patent coverage under a federal court ruling that found the U.S. Patent and Trademark Office had misinterpreted a law governing agency delays in processing patent applications

Start-Up Archer Preps Alzheimer’s Drugs For Phase I

IND filed, company aims to use nilvadipine derivative against soluble amyloid.

Related Content

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel